+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Brain Biomarkers Market - Global Forecast 2026-2032- Product Image
Brain Biomarkers Market - Global Forecast 2026-2032- Product Image
Sale

Brain Biomarkers Market - Global Forecast 2026-2032

  • Report

  • 197 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 6011102
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Brain Biomarkers Market is projected to reach USD 14.43 Billion in 2026. It is expected to continue growing at a CAGR of 18.07%, reaching USD 39.55 Billion by 2032.

Brain biomarkers are moving from specialist research tools into routine clinical decision-making for neurodegenerative disease diagnostics, traumatic brain injury assessment, psychiatric research, and therapy monitoring. The field spans cerebrospinal fluid biomarkers, blood-based biomarkers, neuroimaging biomarkers, electrophysiology, genomics, proteomics, metabolomics, and digital biomarkers captured through wearables and connected devices.

The World Health Organization reports more than 55 million people living with dementia worldwide and nearly 10 million new cases each year, while neurological conditions affect more than 3 billion people globally. For diagnostic providers, this creates a clear opportunity to build validated, scalable, and clinically interpretable brain biomarker workflows that support earlier detection, differential diagnosis, patient stratification, and longitudinal disease monitoring.

Transformative Shifts in the Brain Biomarkers Landscape

The brain biomarkers landscape is shifting toward earlier detection, less invasive sampling, and biomarker-confirmed patient stratification. FDA approvals of anti-amyloid therapies such as lecanemab in 2023 and donanemab in 2024 have increased the need for amyloid and tau confirmation before treatment decisions, strengthening demand for PET imaging, CSF testing, and validated blood-based assays.

Clinical adoption is also changing as neurology moves from symptom-led diagnosis to biology-led assessment. The 2024 Alzheimer’s Association criteria emphasize biomarker evidence, while hospitals and reference laboratories are investing in standardized pre-analytics, longitudinal monitoring, and integrated reports that combine biomarker results with cognitive, imaging, genetic, and clinical context. This shift is also raising expectations for quality control, cut-off harmonization, clinician education, and equitable access to advanced neurological diagnostics.

Cumulative Impact of Artificial Intelligence on Brain Biomarkers

Artificial intelligence is accelerating brain biomarker interpretation by improving image quantification, pattern recognition, and multimodal risk modeling. FDA public listings show rapid growth in authorized AI and machine learning-enabled medical devices, with medical imaging representing the largest category and neurology-related applications expanding.

For diagnostic providers, AI can reduce reader variability in MRI and PET analysis, support automated segmentation of brain structures, and integrate blood, CSF, genetic, electrophysiology, and digital data into clinically useful probability scores. However, adoption must be anchored in transparent validation, demographic bias assessment, cybersecurity controls, data provenance, explainability, and clinician oversight to meet laboratory, hospital, payer, and regulator expectations.

Key Regional Insights for Brain Biomarkers

North America leads clinical implementation because the United States combines advanced neurology networks, FDA-cleared diagnostic pathways, National Institutes of Health-backed research, large Alzheimer’s disease cohorts, and payer frameworks tied to evidence generation. Canada supports adoption through public research institutions, memory clinics, and provincial health systems, although reimbursement pathways, test availability, and access to advanced imaging vary by jurisdiction.

Europe benefits from coordinated dementia strategies, strong academic consortia, and European Union regulation that is raising evidence expectations for in vitro diagnostics. The region is strengthening standardization for CSF, blood-based, and imaging biomarkers, while differences in national reimbursement and laboratory infrastructure continue to shape adoption. Asia-Pacific is expanding as China, Japan, South Korea, India, and Australia invest in aging-related healthcare capacity, hospital-based neurology, imaging infrastructure, precision medicine, and digital health, supported by rapidly growing demand linked to population aging and neurological disease burden. Latin America is advancing through private diagnostic networks, academic neurology centers, and rising dementia awareness, with Brazil and Mexico serving as important access hubs. The Middle East is increasing investment in specialty care, genomics, advanced imaging, and medical tourism, particularly through high-income health systems. Africa shows growing clinical need for brain biomarker-enabled diagnosis, but adoption is constrained by specialist shortages, affordability, laboratory capacity, and limited access to PET tracers, advanced MRI, and standardized biomarker testing.

Key Group Insights for Brain Biomarkers

The G7 remains central to brain biomarker innovation because the United States, Canada, Japan, Germany, France, Italy, and the United Kingdom host leading pharmaceutical sponsors, dementia cohorts, diagnostic developers, academic medical centers, and regulatory systems that influence global evidence standards. The European Union is important for harmonized evidence generation under the In Vitro Diagnostic Regulation and for cross-border research programs that support assay validation, real-world evidence, data interoperability, and clinical guideline development.

BRICS countries are increasingly relevant as China, India, Brazil, Russia, and South Africa expand neurology care, hospital infrastructure, medical research participation, and clinical trial activity, although access remains uneven across urban and rural populations. ASEAN markets are improving diagnostic access through urban hospital systems, expanding private healthcare, and growing digital health adoption, while the GCC is investing in specialty care, genomics, advanced imaging, and medical tourism to support precision neurology. NATO markets overlap with many high-income health systems where secure health data infrastructure, defense-linked traumatic brain injury research, and advanced rehabilitation programs support biomarker development and implementation.

Key Country Insights for Brain Biomarkers

The United States is the most influential country market because FDA decisions, CMS coverage policies, National Institutes of Health funding, Veterans Health Administration research, and large Alzheimer’s disease cohorts shape global standards for biomarker-confirmed diagnosis and therapy monitoring. Canada emphasizes research-driven adoption through academic hospitals and provincial systems, while Mexico and Brazil represent growing Latin American access markets with rising dementia awareness, expanding private diagnostics, and increasing demand for neurologist-supported testing.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine strong neurology centers with increasing demand for biomarker-confirmed diagnosis, especially in Alzheimer’s disease, Parkinsonian syndromes, multiple sclerosis, and rare neurological conditions. Germany and France benefit from advanced hospital infrastructure and specialist networks, the United Kingdom supports implementation through research-led memory services and health technology evaluation, and Italy and Spain show growing use of imaging and laboratory-based neurological diagnostics. Russia remains shaped by uneven access, local regulatory dynamics, and regional differences in specialist availability.

Across Asia-Pacific, China is scaling neuroscience research, hospital capacity, and precision medicine programs; India offers high-volume unmet need driven by population scale and expanding private healthcare; Japan has strong aging-related demand and established neurological care pathways; South Korea supports technology-led diagnostics, digital health, and hospital-based innovation; and Australia combines clinical research strength with organized specialist networks and public health attention to dementia and brain health.

Actionable Recommendations for Brain Biomarker Leaders

Industry leaders should prioritize clinically validated assays, standardized sample handling, and clear interpretation frameworks that help neurologists act on results. Laboratories should align brain biomarker menus with high-impact use cases such as Alzheimer’s disease, Parkinsonian syndromes, multiple sclerosis, traumatic brain injury, neuroinflammation, and therapy monitoring.

Vendors should build partnerships with academic memory clinics, imaging centers, AI developers, biobanks, and pharmaceutical sponsors. The strongest commercial strategies will combine analytical validity, clinical validity, health-economic evidence, payer engagement, diverse cohort validation, privacy-by-design data governance, and interoperable reporting that fits electronic health record workflows. Leaders should also invest in clinician education, reflex testing protocols, external quality assessment, and real-world evidence programs to support adoption across hospitals, reference laboratories, and specialty neurology practices.

Research Methodology for Brain Biomarker Analysis

This executive summary is grounded in secondary research from public health agencies, regulatory databases, peer-reviewed neurology literature, clinical guideline updates, and publicly available institutional disclosures. Sources considered include the World Health Organization, U.S. FDA, CMS, NIH, Alzheimer’s Association, and major international neurology publications.

The methodology emphasizes verified disease-burden data, regulatory milestones, technology adoption evidence, clinical guideline direction, and regional healthcare infrastructure indicators. Insights were synthesized to support executive decision-making while avoiding unsupported market-size claims, promotional language, company references, or unverified performance comparisons. Regional and country narratives were developed by triangulating public health burden, regulatory readiness, specialty care capacity, imaging and laboratory access, and the maturity of precision neurology infrastructure.

Conclusion on the Brain Biomarkers Opportunity

Brain biomarkers are becoming essential to precision neurology as treatment selection, diagnosis, and monitoring increasingly require biological confirmation. The commercial and clinical opportunity is strongest where diagnostic accuracy, clinical workflow integration, reimbursement evidence, and scalable laboratory operations converge.

Diagnostic providers that invest now in validated blood, CSF, imaging, electrophysiology, genetic, and digital biomarker capabilities can strengthen their role in the next generation of neurological care. Success will depend on quality systems, standardized pre-analytics, AI governance, secure data integration, clinician trust, and evidence that demonstrates better decision-making for patients and health systems.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Brain Biomarkers Market, by Biomarker Type
7.1. Introduction
7.2. Imaging Biomarkers
7.2.1. MRI Biomarkers
7.2.2. Nuclear Imaging Biomarkers
7.2.3. CT-Based Biomarkers
7.3. Molecular Biomarkers
7.3.1. Genomic Biomarkers
7.3.2. Proteomic Biomarkers
7.3.3. Metabolomic Biomarkers
7.3.4. Lipidomic Biomarkers
7.3.5. Transcriptomic Biomarkers
7.4. Electrophysiological Biomarkers
7.4.1. Electroencephalography Biomarkers
7.4.2. Magnetoencephalography Biomarkers
7.4.3. Evoked Potential Biomarkers
7.5. Digital Biomarkers
7.5.1. Wearable-Derived Biomarkers
7.5.2. Smartphone-Based Biomarkers
7.5.3. Digital Phenotyping Biomarkers
8. Brain Biomarkers Market, by Sample Type
8.1. Introduction
8.2. Blood
8.2.1. Plasma
8.2.2. Serum
8.3. Cerebrospinal Fluid
8.4. Saliva
8.5. Urine
8.6. Brain Tissue
9. Brain Biomarkers Market, by Technology
9.1. Introduction
9.2. Magnetic Resonance Imaging
9.3. Positron Emission Tomography
9.4. Computed Tomography
9.5. Next-Generation Sequencing
9.6. Electroencephalography
9.7. Mass Spectrometry
9.8. Microarray
10. Brain Biomarkers Market, by Clinical Indication
10.1. Introduction
10.2. Neurodegenerative Disorders
10.3. Psychiatric Disorders
10.4. Neurodevelopmental Disorders
10.5. Traumatic Brain Injury
10.6. Stroke & Cerebrovascular Disorders
10.7. Brain Tumors
10.8. Neuroinflammatory & Demyelinating Disorders
10.9. Central Nervous System Infections
10.10. Epilepsy & Seizure Disorders
11. Brain Biomarkers Market, by Application
11.1. Introduction
11.2. Screening & Risk Assessment
11.3. Diagnosis
11.4. Prognosis
11.5. Treatment Response Monitoring
11.6. Drug Discovery & Clinical Research
12. Brain Biomarkers Market, by End User
12.1. Introduction
12.2. Contract Research Organizations
12.3. Diagnostic Laboratories & Imaging Centers
12.4. Hospitals
12.5. Pharmaceutical & Biotechnology Companies
12.6. Academic & Research Institutes
12.7. Specialty Neurology & Psychiatry Clinics
12.8. Government & Public Health Institutions
13. Brain Biomarkers Market, by Region
13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Latin America
13.5. Middle East
13.6. Africa
14. Brain Biomarkers Market, by Group
14.1. NATO
14.2. G7
14.3. BRICS
14.4. European Union
14.5. GCC
14.6. ASEAN
15. Brain Biomarkers Market, by Country
15.1. United States
15.2. China
15.3. India
15.4. Germany
15.5. Japan
15.6. United Kingdom
15.7. Canada
15.8. Brazil
15.9. France
15.10. Mexico
15.11. Italy
15.12. Spain
15.13. Russia
15.14. Australia
15.15. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Abbott Laboratories
17.2. F. Hoffmann-La Roche Ltd
17.3. Thermo Fisher Scientific Inc.
17.4. Siemens Healthineers AG
17.5. Revvity, Inc.
17.6. GE HealthCare Technologies Inc.
17.7. Illumina, Inc.
17.8. Koninklijke Philips N.V.
17.9. Merck KGaA
17.10. DiaSorin S.p.A.
17.11. Danaher Corporation
17.12. QIAGEN N.V.
17.13. Bio-Rad Laboratories, Inc.
17.14. Bio-Techne Corporation
17.15. Fujirebio Inc.
17.16. Biogen, Inc.
17.17. Altoida
17.18. ANT Neuro
17.19. BioSensics, LLC
17.20. BrainScope Company Inc
17.21. Bruker Corporation
17.22. C2N Diagnostics
17.23. Cortechs.ai
17.24. EMOTIV
17.25. g.tec medical engineering GmbH
17.26. Hologic, Inc.
17.27. IXICO plc
17.28. Lantheus Holdings, Inc.
17.29. Linus Health
17.30. Myriad Genetics, Inc.
17.31. Neurotrack Technologies, Inc.
17.32. Quanterix Corporation
17.33. Quibim, S.L.
17.34. RUNE LABS, INC.
17.35. Synaptive Medical Inc.
List of Figures
FIGURE 1. GLOBAL BRAIN BIOMARKERS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL BRAIN BIOMARKERS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL BRAIN BIOMARKERS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL BRAIN BIOMARKERS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL BRAIN BIOMARKERS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL BRAIN BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL BRAIN BIOMARKERS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL BRAIN BIOMARKERS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL BRAIN BIOMARKERS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL IMAGING BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL IMAGING BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL IMAGING BIOMARKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL MRI BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL MRI BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL MRI BIOMARKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL NUCLEAR IMAGING BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL NUCLEAR IMAGING BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL NUCLEAR IMAGING BIOMARKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL CT-BASED BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL CT-BASED BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL CT-BASED BIOMARKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL MOLECULAR BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL MOLECULAR BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL MOLECULAR BIOMARKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL GENOMIC BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL GENOMIC BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL GENOMIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL PROTEOMIC BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL PROTEOMIC BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL PROTEOMIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL METABOLOMIC BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL METABOLOMIC BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL METABOLOMIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL LIPIDOMIC BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL LIPIDOMIC BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL LIPIDOMIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL TRANSCRIPTOMIC BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL TRANSCRIPTOMIC BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL TRANSCRIPTOMIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL ELECTROPHYSIOLOGICAL BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL ELECTROPHYSIOLOGICAL BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL ELECTROPHYSIOLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL ELECTROENCEPHALOGRAPHY BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL ELECTROENCEPHALOGRAPHY BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL ELECTROENCEPHALOGRAPHY BIOMARKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL MAGNETOENCEPHALOGRAPHY BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL MAGNETOENCEPHALOGRAPHY BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL MAGNETOENCEPHALOGRAPHY BIOMARKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL EVOKED POTENTIAL BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL EVOKED POTENTIAL BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL EVOKED POTENTIAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL WEARABLE-DERIVED BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL WEARABLE-DERIVED BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL WEARABLE-DERIVED BIOMARKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL SMARTPHONE-BASED BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL SMARTPHONE-BASED BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL SMARTPHONE-BASED BIOMARKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL DIGITAL PHENOTYPING BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL DIGITAL PHENOTYPING BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL DIGITAL PHENOTYPING BIOMARKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL BLOOD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL BLOOD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL BLOOD MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL PLASMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL PLASMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL PLASMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL SERUM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL SERUM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL SERUM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL CEREBROSPINAL FLUID MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL CEREBROSPINAL FLUID MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL CEREBROSPINAL FLUID MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL SALIVA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL SALIVA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL SALIVA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL URINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL URINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL BRAIN TISSUE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL BRAIN TISSUE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL BRAIN TISSUE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL MAGNETIC RESONANCE IMAGING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL MAGNETIC RESONANCE IMAGING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL MAGNETIC RESONANCE IMAGING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL COMPUTED TOMOGRAPHY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL COMPUTED TOMOGRAPHY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL ELECTROENCEPHALOGRAPHY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL ELECTROENCEPHALOGRAPHY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL ELECTROENCEPHALOGRAPHY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL MICROARRAY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL MICROARRAY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL MICROARRAY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL NEURODEGENERATIVE DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL NEURODEGENERATIVE DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL NEURODEGENERATIVE DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL PSYCHIATRIC DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL PSYCHIATRIC DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL PSYCHIATRIC DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL NEURODEVELOPMENTAL DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL NEURODEVELOPMENTAL DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL NEURODEVELOPMENTAL DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL TRAUMATIC BRAIN INJURY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL TRAUMATIC BRAIN INJURY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL TRAUMATIC BRAIN INJURY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL STROKE & CEREBROVASCULAR DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL STROKE & CEREBROVASCULAR DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL STROKE & CEREBROVASCULAR DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL BRAIN TUMORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL BRAIN TUMORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL BRAIN TUMORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL NEUROINFLAMMATORY & DEMYELINATING DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL NEUROINFLAMMATORY & DEMYELINATING DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL NEUROINFLAMMATORY & DEMYELINATING DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL CENTRAL NERVOUS SYSTEM INFECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL CENTRAL NERVOUS SYSTEM INFECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL CENTRAL NERVOUS SYSTEM INFECTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL EPILEPSY & SEIZURE DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL EPILEPSY & SEIZURE DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL EPILEPSY & SEIZURE DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL SCREENING & RISK ASSESSMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL SCREENING & RISK ASSESSMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL SCREENING & RISK ASSESSMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL DIAGNOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL DIAGNOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 136. GLOBAL DIAGNOSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 137. GLOBAL PROGNOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 138. GLOBAL PROGNOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 139. GLOBAL PROGNOSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL TREATMENT RESPONSE MONITORING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 141. GLOBAL TREATMENT RESPONSE MONITORING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 142. GLOBAL TREATMENT RESPONSE MONITORING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 143. GLOBAL DRUG DISCOVERY & CLINICAL RESEARCH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 144. GLOBAL DRUG DISCOVERY & CLINICAL RESEARCH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 145. GLOBAL DRUG DISCOVERY & CLINICAL RESEARCH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 146. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 147. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 148. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 149. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 150. GLOBAL DIAGNOSTIC LABORATORIES & IMAGING CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 151. GLOBAL DIAGNOSTIC LABORATORIES & IMAGING CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 152. GLOBAL DIAGNOSTIC LABORATORIES & IMAGING CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 153. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 154. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 155. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 156. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 157. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 158. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 159. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 160. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 161. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 162. GLOBAL SPECIALTY NEUROLOGY & PSYCHIATRY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 163. GLOBAL SPECIALTY NEUROLOGY & PSYCHIATRY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 164. GLOBAL SPECIALTY NEUROLOGY & PSYCHIATRY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 165. GLOBAL GOVERNMENT & PUBLIC HEALTH INSTITUTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 166. GLOBAL GOVERNMENT & PUBLIC HEALTH INSTITUTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 167. GLOBAL GOVERNMENT & PUBLIC HEALTH INSTITUTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 168. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 169. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 170. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 171. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY IMAGING BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 172. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 173. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY ELECTROPHYSIOLOGICAL BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 174. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 175. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 176. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 177. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 178. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 179. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 180. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 181. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 182. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 183. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY IMAGING BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 184. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 185. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY ELECTROPHYSIOLOGICAL BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 186. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 187. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 188. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 189. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 190. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 191. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 192. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 193. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 194. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 195. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY IMAGING BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 196. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 197. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY ELECTROPHYSIOLOGICAL BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 198. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 199. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 200. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 201. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 202. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 203. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 204. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 205. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 206. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 207. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY IMAGING BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 208. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 209. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY ELECTROPHYSIOLOGICAL BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 210. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 211. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 212. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 213. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 214. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 215. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 216. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 217. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 218. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 219. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY IMAGING BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 220. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 221. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY ELECTROPHYSIOLOGICAL BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 222. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 223. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 224. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 225. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 226. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 227. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 228. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 229. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 230. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 231. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY IMAGING BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 232. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 233. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY ELECTROPHYSIOLOGICAL BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 234. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 235. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 236. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 237. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 238. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 239. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 240. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 241. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 242. NATO BRAIN BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 243. NATO BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 244. NATO BRAIN BIOMARKERS MARKET SIZE, BY IMAGING BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 245. NATO BRAIN BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 246. NATO BRAIN BIOMARKERS MARKET SIZE, BY ELECTROPHYSIOLOGICAL BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 247. NATO BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 248. NATO BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 249. NATO BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 250. NATO BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 251. NATO BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 252. NATO BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 253. NATO BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 254. G7 BRAIN BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 255. G7 BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 256. G7 BRAIN BIOMARKERS MARKET SIZE, BY IMAGING BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 257. G7 BRAIN BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 258. G7 BRAIN BIOMARKERS MARKET SIZE, BY ELECTROPHYSIOLOGICAL BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 259. G7 BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 260. G7 BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 261. G7 BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 262. G7 BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 263. G7 BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 264. G7 BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 265. G7 BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 266. BRICS BRAIN BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 267. BRICS BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 268. BRICS BRAIN BIOMARKERS MARKET SIZE, BY IMAGING BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 269. BRICS BRAIN BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 270. BRICS BRAIN BIOMARKERS MARKET SIZE, BY ELECTROPHYSIOLOGICAL BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 271. BRICS BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 272. BRICS BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 273. BRICS BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 274. BRICS BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 275. BRICS BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 276. BRICS BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 277. BRICS BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 278. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 279. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 280. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY IMAGING BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 281. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 282. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY ELECTROPHYSIOLOGICAL BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 283. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 284. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 285. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 286. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 287. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 288. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 289. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 290. GCC BRAIN BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 291. GCC BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 292. GCC BRAIN BIOMARKERS MARKET SIZE, BY IMAGING BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 293. GCC BRAIN BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 294. GCC BRAIN BIOMARKERS MARKET SIZE, BY ELECTROPHYSIOLOGICAL BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 295. GCC BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 296. GCC BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 297. GCC BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 298. GCC BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 299. GCC BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 300. GCC BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 301. GCC BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 302. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 303. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 304. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY IMAGING BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 305. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 306. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY ELECTROPHYSIOLOGICAL BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 307. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 308. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 309. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 310. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 311. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 312. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 313. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 314. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 315. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 316. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 317. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY IMAGING BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 318. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 319. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY ELECTROPHYSIOLOGICAL BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 320. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 321. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 322. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 323. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 324. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 325. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 326. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 327. CHINA BRAIN BIOMARKERS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 328. CHINA BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 329. CHINA BRAIN BIOMARKERS MARKET SIZE, BY IMAGING BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 330. CHINA BRAIN BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 331. CHINA BRAIN BIOMARKERS MARKET SIZE, BY ELECTROPHYSIOLOGICAL BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 332. CHINA BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 333. CHINA BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 334. CHINA BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 335. CHINA BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 336. CHINA BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 337. CHINA BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 338. CHINA BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 339. INDIA BRAIN BIOMARKERS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 340. INDIA BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 341. INDIA BRAIN BIOMARKERS MARKET SIZE, BY IMAGING BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 342. INDIA BRAIN BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 343. INDIA BRAIN BIOMARKERS MARKET SIZE, BY ELECTROPHYSIOLOGICAL BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 344. INDIA BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 345. INDIA BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 346. INDIA BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 347. INDIA BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 348. INDIA BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 349. INDIA BRAIN BIOMARKERS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 350. INDIA BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 351. GERMANY BRAIN BIOMARKERS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 352. GERMANY BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2017-2032 (USD MILLION)
TABLE 353. GERMANY BRAIN BIOMARKERS MARKET SIZE, BY IMAGING BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 354. GERMANY BRAIN BIOMARKERS MARKET SIZE, BY MOLECULAR BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 355. GERMANY BRAIN BIOMARKERS MARKET SIZE, BY ELECTROPHYSIOLOGICAL BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 356. GERMANY BRAIN BIOMARKERS MARKET SIZE, BY DIGITAL BIOMARKERS, 2017-2032 (USD MILLION)
TABLE 357. GERMANY BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 358. GERMANY BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2017-2032 (USD MILLION)
TABLE 359. GERMANY BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 360. GERMANY BRAIN BIOMARKERS MARKET SIZE, BY CLINICAL INDICATION, 2017-2032 (USD MILLION)
TABLE 3

Companies Mentioned

  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific Inc.
  • Siemens Healthineers AG
  • Revvity, Inc.
  • GE HealthCare Technologies Inc.
  • Illumina, Inc.
  • Koninklijke Philips N.V.
  • Merck KGaA
  • DiaSorin S.p.A.
  • Danaher Corporation
  • QIAGEN N.V.
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Fujirebio Inc.
  • Biogen, Inc.
  • Altoida
  • ANT Neuro
  • BioSensics, LLC
  • BrainScope Company Inc
  • Bruker Corporation
  • C2N Diagnostics
  • Cortechs.ai
  • EMOTIV
  • g.tec medical engineering GmbH
  • Hologic, Inc.
  • IXICO plc
  • Lantheus Holdings, Inc.
  • Linus Health
  • Myriad Genetics, Inc.
  • Neurotrack Technologies, Inc.
  • Quanterix Corporation
  • Quibim, S.L.
  • RUNE LABS, INC.
  • Synaptive Medical Inc.

Table Information

Report AttributeDetails
No. of Pages197
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 14.43 Billion
Forecasted Market Value ( USD ) by 2032 $ 39.55 Billion
Compound Annual Growth Rate18.0%
Regions CoveredGlobal
No. of Companies Mentioned35

Related Topics

Related Reports

Neurological Biomarkers Market - Global Forecast 2026-2032 - Product Image

Neurological Biomarkers Market - Global Forecast 2026-2032

  • Report
  • 190 Pages
  • Global
From
Digital Neuro Biomarkers Market Report 2026 - Product Image

Digital Neuro Biomarkers Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Neurological Biomarkers Market Size, Share, Trends and Forecast by Type, Application, End Use, and Region, 2026-2034 - Product Image

Neurological Biomarkers Market Size, Share, Trends and Forecast by Type, Application, End Use, and Region, 2026-2034

  • Report
  • 140 Pages
  • Global
From
Neurological Biomarkers - Global Strategic Business Report - Product Image

Neurological Biomarkers - Global Strategic Business Report

  • Report
  • 389 Pages
  • Global
From
Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases - Global Strategic Business Report - Product Image

Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From

About the Neurological Biomarker Market

A neurological biomarker is a biological indicator of a neurological disorder or disease. It is used to diagnose, monitor, and predict the progression of neurological diseases. Neurological biomarkers can be found in a variety of biological samples, such as blood, cerebrospinal fluid, and tissue. They can also be used to measure the effectiveness of treatments. Neurological biomarkers are becoming increasingly important in the field of personalized medicine, as they can provide a more accurate diagnosis and prognosis of neurological diseases. They can also be used to identify potential drug targets and to monitor the progression of neurological diseases. The neurological biomarker market is growing rapidly, driven by the increasing prevalence of neurological diseases, the development of new technologies, and the increasing demand for personalized medicine. The market is expected to continue to grow in the coming years, as more companies enter the market and develop new technologies. Some of the major companies in the neurological biomarker market include Bio-Rad Laboratories, Inc., BioMérieux SA, Abbott Laboratories, Roche Diagnostics, and Siemens Healthineers. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.